Current status of the Finnish boron neutron capture therapy (BNCT) project

Iiro Auterinen, Carita Aschan, Judit Benczik, Markus Färkkilä, Pekka Hiismäki, Karoliina Kaita, Markku Kallio, Antti Kosunen, Martti Kulvik, M. Kärkkäinen, P. Ryynänen, Sauli Savolainen, Tiina Seppälä, Tom Serén, Vesa Tanner, Mika Toivonen, Jyrki Vähätalo, Hanna Ylä-Mella

    Research output: Chapter in Book/Report/Conference proceedingConference abstract in proceedingsScientific

    Abstract

    A research group to carry out clinical application of BNCT was established in Finland in the early 1990's. The neutron irradiations will take place at the Finnish research reactor (FiR 1) operated by VTT in Otaniemi. In April 1996 the new FLUENTALtm neutron moderator developed by VTT was installed and in September a conical beam collimator. Neutron field and dosimetric measurements have confirmed that the epithermal neutron field is suitable for human treatments. In October a thorough renovation of the reactor building has started. The ground and first floor will be converted into a BNCT research and treatment facility. The Monte Carlo based INEL NCT dose planning program rtt_MC has been used in the determination of the brain substitute materials for head phantoms. The program is also used in the healthy tissue tolerance studies. Other efforts in dosimetry include studying the suitability of TL detectors for BNCT. To determine the boron capture dose distribution the boron distribution in the tumour and in the other tissues has to be known in addition to the thermal neutron field. The current efforts on boron bulk-analysis are focused on the methods ICP-AES, PGNA and PIGE. In order to analyse boron distribution at cellular level SIMS will he used combined with freeze-drying and cryosectioning, thus preserving the original boron distribution in the samples. Boron distribution determination in vivo is pursued by radiolabelling boron carriers. Normal tissue tolerance studies in co-operation with CRC Radiobiology Unit, Oxford, England, will contribute towards the verification of the treatment planning, radiation doses, biological effects and radiation safety of BNCT before proceeding to therapies of patients. Boron carrier biodistribution studies of boronophenytalanine (BPA) will be completed in 1998, with data available for the patient treatments.
    Original languageEnglish
    Title of host publicationProceedings of the XXXI Annual Conference of the Finnish Physical Society
    Subtitle of host publicationAbstracts
    EditorsEero Rauhala, M.E. Sainio
    Place of PublicationHelsinki
    PublisherUniversity of Helsinki
    ISBN (Print)951-45-7639-X
    Publication statusPublished - 1997
    MoE publication typeNot Eligible
    EventXXXI Annual Conference of the Finnish Physical Society - Helsinki, Finland
    Duration: 13 Mar 199715 Mar 1997

    Publication series

    SeriesUniversity of Helsinki: Department of Physics. Report Series in Physics
    Volume262
    ISSN0355-5801

    Conference

    ConferenceXXXI Annual Conference of the Finnish Physical Society
    CountryFinland
    CityHelsinki
    Period13/03/9715/03/97

    Fingerprint Dive into the research topics of 'Current status of the Finnish boron neutron capture therapy (BNCT) project'. Together they form a unique fingerprint.

    Cite this